Polepally AR - Search Results

1

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.

Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Badri PS, et al. Among authors: polepally ar. Clin Pharmacokinet. 2016 Mar;55(3):275-95. doi: 10.1007/s40262-015-0317-8. Clin Pharmacokinet. 2016. PMID: 26330025 Free PMC article. Review.

2

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.

Menon RM, Badri PS, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. Menon RM, et al. Among authors: polepally ar. J Hepatol. 2015 Jul;63(1):20-9. doi: 10.1016/j.jhep.2015.01.026. Epub 2015 Jan 31. J Hepatol. 2015. PMID: 25646891 Free article. Clinical Trial.

3

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, Aguilar H, Felizarta F, McGovern B, King M, Polepally AR, Cohen DE. Lalezari J, et al. Among authors: polepally ar. J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1. J Hepatol. 2015. PMID: 25839406 Free article. Clinical Trial.

4

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.

Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Badri PS, et al. Among authors: polepally ar. Antimicrob Agents Chemother. 2015 Oct 12;60(1):105-14. doi: 10.1128/AAC.01778-15. Print 2016 Jan. Antimicrob Agents Chemother. 2015. PMID: 26459906 Free PMC article. Clinical Trial.

5

Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.

Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Feld JJ, et al. Among authors: polepally ar. J Hepatol. 2016 Feb;64(2):301-307. doi: 10.1016/j.jhep.2015.10.005. Epub 2015 Oct 22. J Hepatol. 2016. PMID: 26476290 Free article. Clinical Trial.

6

Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies.

Mensing S, Polepally AR, König D, Khatri A, Liu W, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Mensing S, et al. Among authors: polepally ar. AAPS J. 2016 Jan;18(1):270-80. doi: 10.1208/s12248-015-9846-1. Epub 2015 Nov 23. AAPS J. 2016. PMID: 26597291 Free PMC article.

7

Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.

Polepally AR, King JR, Ding B, Shuster DL, Dumas EO, Khatri A, Chiu YL, Podsadecki TJ, Menon RM. Polepally AR, et al. Clin Pharmacokinet. 2016 Aug;55(8):1003-14. doi: 10.1007/s40262-016-0373-8. Clin Pharmacokinet. 2016. PMID: 26895022 Free PMC article. Clinical Trial.

8

Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.

Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Polepally AR, et al. Clin Pharmacokinet. 2016 Sep;55(9):1091-101. doi: 10.1007/s40262-016-0385-4. Clin Pharmacokinet. 2016. PMID: 27000758 Clinical Trial.

9

Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.

Polepally AR, Badri PS, Eckert D, Mensing S, Menon RM. Polepally AR, et al. Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):333-339. doi: 10.1007/s13318-016-0341-6. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27165046

10

Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.

Polepally AR, Dutta S, Hu B, Podsadecki TJ, Awni WM, Menon RM. Polepally AR, et al. Clin Pharmacol Drug Dev. 2016 Jul;5(4):269-77. doi: 10.1002/cpdd.246. Epub 2016 Jan 24. Clin Pharmacol Drug Dev. 2016. PMID: 27310328 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters